Generic Name and Formulations:
Nefazodone HCl 50mg, 100mg+, 150mg+, 200mg, 250mg; tabs; +scored.
Various generic manufacturers
Indications for Nefazodone:
≥18 years: initially 200mg daily in 2 divided doses; increase in increments of 100–200mg/day in 2 divided doses at 1-week intervals; range 300–600mg/day. Debilitated: initially 100mg daily in 2 divided doses.
<18 years: not recommended.
Concomitant MAOIs, cisapride, carbamazepine; triazolam (see Interactions). Active liver disease. Elevated baseline serum transaminases. History of nefazodone-associated liver dysfunction.
Monitor for liver dysfunction; discontinue if signs of liver disease occur (eg, AST or ALT ≥ 3XULN). Cardio- or cerebrovascular disease. Predisposition to hypotension (eg, dehydration, hypovolemia). Mania/hypomania. Suicidal patients. Seizure disorders. Hepatic cirrhosis. Discontinue and reevaluate if priapism occurs. ECT. Reevaluate periodically. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers.
Allow 14 days after discontinuing an MAOI before starting nefazodone; allow 7 days after discontinuing nefazodone before starting an MAOI. Avoid alcohol. Avoid concomitant triazolam (esp. in elderly); if used, reduce concomitant triazolam dose by 75%. Reduce concomitant alprazolam dose by 50%. Caution with antihypertensives, diuretics, other CNS-active drugs, oral anticoagulants, oral hypoglycemics, aspirin, other highly protein-bound drugs, drugs metabolized by CYP3A4. Risk of rhabdomyolysis with statins metabolized by CYP3A4 (eg, simvastatin, lovastatin, atorvastatin). May potentiate buspirone, haloperidol (reduce dose); cyclosporine, tacrolimus, digoxin (monitor). Discontinue before general anesthesia.
Headache, nausea, dizziness, insomnia, asthenia, agitation, somnolence, dry mouth, constipation, blurred or abnormal vision, confusion, postural hypotension, priapism, others; rare: hepatic failure.
Formerly known under the brand name Serzone.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC